Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide

Shih, Vivianne; Hee, Siew Wan; Chan, Alexandre

doi:10.1345/aph.1l437

Cited by 56 publications

(60 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A history of morning sickness has been suggested to increase CINV risk as well [28]. Findings from Warr et al [27] further support this, with a significant association between morning sickness history and CINV (p = 0.0007).…”

Section: History Of Morning Sicknessmentioning

confidence: 84%

“…Patients with a history of motion sickness have been reported to be more prone to CINV [28]. However, the study by Warr et al [27] found this risk factor to be insignificant (p > 0.05).…”

Section: History Of Motion Sicknessmentioning

confidence: 99%

“…Patients who do not consume alcohol have a higher predisposition towards CINV [28]. While an optimal alcohol consumption level has yet to be determined, both Hesketh et al [26] (p = 0.027) and Warr et al [27] (p = 0.0048) found that consumption of ≥5 drinks a day significantly improved CINV control, while non-drinkers experienced the worst CINV.…”

Section: History Of Alcohol Consumptionmentioning

confidence: 99%

“…The emetogenicity of the regimen increases CINV risk [28]. As AC-based regimens exhibit HEC patterns, populations with a greater proportion of patients on AC-based regimens rather than less emetogenic regimens may have poorer CINV control.…”

Section: Chemotherapy Regimenmentioning

confidence: 99%

See 3 more Smart Citations

Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?

Yap¹,

Leong²,

Chan³

2012

JCT

Self Cite

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) are distressing side effects of chemotherapy. Neurokinin-1 receptor antagonists (NK1-RAs) have been incorporated in the contemporary management of CINV. However, clinical studies on NK1-RAs have shown mixed results in reducing CINV risk. Most studies focused on the use of aprepitant (APR) and casopitant (CAS) in breast cancer patients receiving AC-type (doxorubicin and cyclophosphamide) chemotherapy. In this study, we compared the study design and clinical efficacies of these NK1-RAs in reducing CINV risk. Among the selected eight studies, 4 APR Randomized Controlled Trials (RCTs), 2 APR Observational Studies (OSs) and 2 CAS RCTs were identified. Patient-related characteristics such as the proportion of females (60.0% -100.0%), age (46.5 -59.5 years), histories of motion (5.6% -47.0% in NK1-RA arms) and morning sicknesses (14.2% -45.0% in NK1-RA arms) and types of antiemetic regimens; as well as chemotherapy-related characteristics such as the proportion of patients on AC chemotherapy (15.0% -100.0%) varied greatly. In terms of efficacies, both APR and CAS improved overall CR and vomiting in majority of the studies. None of the studies, however, demonstrated that NK1-RA could provide adequate nausea control. To conclude, NK1-RAs are effective in improving vomiting and overall CR, but not useful in controlling nausea or attaining CC, the ideal CINV endpoint. A shift in paradigm is needed for future CINV research. As healthcare providers continue to strive for optimum CINV control in their patients, we hope this review can help them make better informed clinical decisions.

show abstract

Section: History Of Morning Sicknessmentioning

confidence: 84%

“…Patients with a history of motion sickness have been reported to be more prone to CINV [28]. However, the study by Warr et al [27] found this risk factor to be insignificant (p > 0.05).…”

Section: History Of Motion Sicknessmentioning

confidence: 99%

Section: History Of Alcohol Consumptionmentioning

confidence: 99%

Section: Chemotherapy Regimenmentioning

confidence: 99%

See 2 more Smart Citations

Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?

Yap¹,

Leong²,

Chan³

2012

JCT

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a study by Shih et al, 14 history of chemotherapy-induced nausea was a significant risk factor influencing both acute and delayed nausea. A history of motion sickness was also a significant risk factor that influenced delayed vomiting.…”

Section: Discussionmentioning

confidence: 98%

Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer

Fleishman

Mahajan

Rosenwald

et al. 2012

JOP

View full text Add to dashboard Cite

Purpose: To measure the prevalence of nausea and vomiting 2 to 5 days after oxaliplatin-based chemotherapy. Patients and Methods:Sixty-four patients (55% men; 44% women) enrolled onto this cross-sectional study. Fifty-three (83%) had colon cancer and received oxaliplatin biweekly. Eleven (17%) had rectal cancer and received oxaliplatin weekly. We collected data on 23 patients for the first cycle and on 41 patients for the first two cycles, for a total of 105 cycles. Nausea and vomiting was graded using Common Toxicity Criteria. Patients maintained a 7-day postinfusion diary of nausea and vomiting and antiemetic use.Results: All patients received antiemetics and steroids on day 1 of each cycle. For patients with data collected for both cycles, the occurrence of nausea was the same during cycles one and two. Thirty-nine percent used rescue antiemetics in cycle one, and 34% did so in cycle two. Sixty-eight percent of men reported no nausea in cycle one compared with 33% of women; for cycle two, these figures were 67% and 36%, respectively. Eighty-nine percent of patients reported no vomiting in cycle one, and 85% did so in cycle two. Seven patients (11%) had a history of motion sickness; 13 of 28 women (46%) reported history of pregnancyinduced morning sickness. Palonosetron slightly but significantly reduced the occurrence of nausea. Female sex and history of chemotherapy were significant risk factors for nausea. Conclusion:Delayed nausea associated with oxaliplatin was well controlled and evenly divided between grades 1 and 2; vomiting was rare. Factors associated with nausea were intrinsic to the patient and mostly unrelated to the antiemetics used. Sex and previous experience with emesis should be considered for efficient antiemetic management.

show abstract

Overlapping Phenotypes

Horn

2013

Pain Genetics

View full text Add to dashboard Cite

Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide

Cited by 56 publications

References 34 publications

Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?

Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?

Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer

Overlapping Phenotypes

Contact Info

Product

Resources

About